Who Owns Wegovy?

Novo Nordisk has committed to achieving carbon neutrality across its production facilities by 2030 and across its entire value chain by 2045. Wegovy manufacturing plants in Denmark and the United States are being upgraded with renewable energy sources and energy-efficient equipment.

Novo Nordisk maintains supplier standards for pharmaceutical ingredients and conducts regular supplier audits. The company has implemented programs for proper disposal of unused medications and medical waste.

Novo Nordisk offers patient assistance programs to improve access to Wegovy for patients who face financial barriers. The company works with healthcare providers, insurers, and government programs to facilitate coverage and reimbursement.

The environmental impact of GLP-1 medications has drawn attention. The plastic injection pens used for Wegovy create medical waste, and Novo Nordisk has explored recycling programs for pen devices. The company reports progress in its annual sustainability report.

Wegovy has been recognized as one of the most significant pharmaceutical innovations of the decade. The STEP clinical trial program, published in the New England Journal of Medicine, demonstrated unprecedented weight loss results for a pharmacological treatment.

The SELECT cardiovascular outcomes trial, published in 2023, was recognized as a landmark study demonstrating that a weight loss medication could reduce cardiovascular events. This data led to an FDA label expansion for Wegovy in 2024.

Wegovy's commercial performance has been recognized by financial analysts as one of the most successful pharmaceutical launches in history. The brand generated over $10 billion in annual revenue by 2024, making semaglutide one of the best-selling pharmaceutical compounds globally.

Lowered Full-Year Outlook (August 2026): Novo Nordisk cut its full-year sales and profit outlook, citing lower-than-expected US demand for Wegovy and competition from Eli Lilly's Zepbound. The announcement triggered a significant stock price decline. The company now projects full-year sales growth of 12-16% at constant currency, down from previous guidance. The cut raised questions about whether semaglutide is losing ground to tirzepatide in the obesity market.

Supply Shortages (2021-2024): Wegovy experienced severe supply shortages from launch through 2024, driven by demand that exceeded Novo Nordisk's production capacity. The shortages led to treatment interruptions for patients and criticism from patient advocacy groups. Novo Nordisk invested billions in expanding manufacturing but struggled to keep pace. The FDA placed Wegovy on its shortage list, which allowed compounders to produce copycat versions.

Compounded Semaglutide Controversy: During the supply shortage, the FDA allowed compounding pharmacies to produce copycat semaglutide. When supply improved, the FDA moved to remove semaglutide from the shortage list in late 2024, triggering a legal battle with compounding pharmacies. Novo Nordisk sued several compounders for selling unapproved versions of Wegovy. The Outsourcing Facilities Association challenged the FDA's decision in court. As of 2026, compounded semaglutide is being phased out, though some compounders continue to fight the restrictions.

Pricing and Access: Wegovy's list price of approximately $1,349 per month in the United States has generated controversy about healthcare affordability. Many insurance plans do not cover anti-obesity medications. Medicare Part D does not cover Wegovy for weight management, though coverage has expanded for cardiovascular risk reduction. Patient advocacy groups have argued that obesity should be treated like other chronic conditions for insurance purposes.

Side Effects and Safety: Wegovy can cause gastrointestinal side effects including nausea, vomiting, and diarrhea. Rare but serious adverse events including pancreatitis and gallbladder problems have been reported. The FDA has required labeling about the risk of thyroid C-cell tumors based on animal studies. Healthcare providers must carefully select patients and monitor for adverse events.

Off-Label Use Concerns: There has been concern about off-label use of Wegovy for cosmetic weight loss by patients who do not meet clinical obesity criteria. Social media promotion of GLP-1 medications has contributed to demand from non-medical users, leading to debates about appropriate prescribing practices.